Biogen’s top executive crew has a big credibility issue. And they seem determined to make it worse
First came the pandemic “superspreader” event at the Marriott Long Wharf that created a simmering public relations nightmare for Biogen $BIIB. And now here comes the big credibility issue on their lead Phase III Alzheimer’s drug that will likely dog their steps for months to come — at the least.
Yesterday’s Q&A with analysts on their Q1 call turned into a tough — and extremely unusual — press conference as analysts repeatedly pushed hard for some specifics on just why the big biotech decided to push back its timeline on the aducanumab filing from “early 2020” to sometime in Q3.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.